MarketBeat on MSN
CRISPR Therapeutics gains after earnings as pipeline hope grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...
CRISPR Therapeutics (NASDAQ:CRSP) executives highlighted progress across its oncology and autoimmune cell therapy pipeline ...
Durham, North Carolina and Oxford, United Kingdom, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pairwise, a global innovator in agriculture, today ...
CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.
Antibiotic resistance is racing toward a global crisis, with “superbugs” projected to cause over 10 million deaths annually by 2050. Now, scientists at UC San Diego have unveiled a powerful new CRISPR ...
A version of this Priestley Medal address will be presented at the American Chemical Society Spring 2026 meeting ...
A sales partner offered a ray of hope that this company couldn't for itself.
TDC on MSN
Feeding 10 billion people, the farm technology revolution from robots and drones to CRISPR crops
As the world races toward 10 billion people, farming is being reinvented by machines, data, and biology, from robotic ...
CRISPR Therapeutics AG CRSP on Friday reported its fourth-quarter and full-year 2025 financial results, highlighting ...
If you are wondering whether CRISPR Therapeutics at around US$53.52 is offering good value today, you are not alone. The stock often attracts investors who care about price versus potential. The share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results